Trial: 201903114

A Single-Arm, Open-Label, Pilot Study and Expansion Study of JAK Inhibitor Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome after T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation

Phase

I

Principal Investigator

Abboud, Ramzi

Disease Site

Hodgkin Lymphoma; Lymphoid Leukemia; Myeloid and Monocytic Leukemia; Non-Hodgkin Lymphoma; Other Hematopoietic

Learn more about this study at: clinicaltrials.gov